The Global Molecular Pharming Market Size is predicted to witness a 7.46% CAGR during the forecast period for 2023-2031.
In a biotechnological program known as "molecular farming," crops are genetically altered to create proteins and chemicals for industrial and pharmaceutical uses. The vast majority of developing nations cannot pay the enormous price of medical treatments brought on by the already-used techniques. Farmers are urged by mounting environmental concerns to reorient their efforts toward sustainable agriculture methods, including resource conservation. This has increased the demand for better crop nutrition and protection, supporting market expansion.
The molecular farming market growth is also anticipated to continue growing due to the rising demand for modern medicines and pharmaceuticals. Increasing environmental concerns are pressuring farmers to refocus their efforts on sustainable agriculture practices, including resource conservation. As a result, there is a tremendous need for improved crop nutrition and protection, which has helped the molecular farming industry to grow.
- In April 2022, Satellite Bio introduced a unique method for bioengineering tissues. This company has expertise in synthetic biology, regenerative medicine, cell therapy, cell biology, and tissue engineering.
Some of the Molecular Pharming market players are:
- Agrenvec S.L
- Bright Biotech
- Core Biogenesis
- Diamante SRL
- Leaf Systems International Limited
- Medicago Inc
- Meristem Therapeutics S.A. (Ventria Bioscience)
- Moolec Science Limited
- Nobell Foods
- ORF Genetics
- Pfizer, Inc.
- ProdiGene Inc
- Protalix Biotherapeutics, Inc
- Tiamat Sciences
The molecular pharming market is segmented on the crop type, technology, applications and end users. The market is segmented based on crop type: maize, barley, tobacco, safflower, rice and alfalfa. Based on technology, the molecular pharming market is segmented into gene guns, agroinfiltration, electroporation, agrobacterium-mediated gene transfer and Others. Based on the application, the molecular pharming market is segmented into recombinant antibodies, hormones, vaccines, industrial enzymes, proteins & protein-based materials, technical reagents, and nutritional products. Based on end-use, the molecular pharming market is segmented into biotechnology & pharmaceutical companies, contract manufacturing organizations, and others.
Based On Technology, The Gene Gun Segment Is A Major Contributor To The Molecular Pharming Market
The market's leading segment is gene guns. A gene gun is a tool that is used to transport external (exogenous) DNA, RNA, or proteins to the cells in a way that allows the biological particles to be reproduced or translated using the plant reproduction system and to multiply the necessary biologics without the need of low-cost microbial systems.
The process known as agroinfiltration combines plant biotechnology and agriculture. To mass-create the desired protein, the approach simultaneously stimulates transitory gene expression in a plant, part of a plant, or numerous plants. A microbiological technique called electroporation, also referred to as electro-permeabilization, employs an electric field to make cells more permeable via their membranes. When utilized in plant biotechnology, these cells are preferably plant cells.
The Biotechnology & Pharmaceutical Companies Segment Witnessed Growth At A Rapid Rate
Biotechnology & pharmaceutical companies grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Strong government support for the market is demonstrated by programs aiming to modernize the regulatory environment, enhance approval procedures and reimbursement practices, and standardize clinical studies. Biotechnological methods are expanding significantly, with examples including genetic engineering, DNA fingerprinting, and stem cell technologies.
The North American Molecular Pharming Market Holds A Significant Regional Revenue Share
The North American molecular pharming market is expected to register the highest market share in revenue shortly. The region's market has a high revenue due to factors including expanding government efforts that boost the implementation of modern agriculture technologies and established infrastructure. Additionally, a robust administrative framework helps farmers acquire the necessary skills for using and maintaining molecular farming equipment.
In addition, Asia Pacific is projected to grow rapidly in the global molecular pharming market. In emerging nations like India, Sri Lanka, and Nigeria, various government programs are being carried out to promote the adoption of cutting-edge molecular farming technologies and consequently increase productivity.
Molecular Pharming Market Report Scope:
Growth rate CAGR
CAGR of 7.46% from 2023 to 2031
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031
2019 to 2022
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends
Crop Type, Technology, Applications And End Users
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia
Meristem Therapeutics S.A. (Ventria Bioscience),, Moolec Science Limited, Leaf Systems International Limite, Agrenvec S.L, Diamante SRL, ORF Genetics, Pfizer, Inc., Medicago Inc, Protalix Biotherapeutics, Inc and ProdiGene Inc.
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and available payment methods
Explore pricing alternatives that are customized to your particular study requirements.